Prophylaxis of fungal infections in liver transplant patients
New data presented at the 16th Congress of the European Society for Organ Transplantation (ESOT) demonstrate that in liver transplant patients, initiating ADVAGRAF™ prolonged-release capsules (tacrolimus) therapy immediately post transplant, at a dose 25% lower than the upper recommended limit,(8) in combination with basiliximab, results in significantly better renal function and a lower incidence of acute organ rejection when compared with standard dose ADVAGRAF therapy.(9) Furthermore, delaying the introduction of ADVAGRAF post transplant gives no additional advantage in terms of renal function.(9) (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 12, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Transplantation Latest News Source Type: news
Tacrolimus Dose in Pediatric Liver TransplantationTacrolimus Dose in Pediatric Liver Transplantation
Tacrolimus has become the mainstay of immunosuppressive treatment in pediatric liver transplantation. How does the CYP3A5 genotype effect tacrolimus dose requirements? Pharmacogenomics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2013 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news
Astagraf XL (Tacrolimus Extended-release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2013 Category: Drugs & Pharmacology Source Type: news
Long-Release Tacrolimus Wins FDA Nod
(MedPage Today) -- An extended-release formulation of tacrolimus (Astagraf XL) for preventing kidney transplant rejection has been approved by the FDA, its manufacturer said. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 22, 2013 Category: Primary Care Source Type: news
Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2013 Category: Pharmaceuticals Source Type: news
Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Media News)
Source: Roche Media News - July 19, 2013 Category: Pharmaceuticals Source Type: news
New Automated Immunosuppressive Drug Assays Improve Therapeutic Drug Monitoring for Transplant Patients
For the first time, certain immunosuppressive drug (ISD) assays can now be performed automatically on cobas® modular platforms, allowing laboratories to consolidate testing for a wide range of transplant testing/monitoring assays onto a single platform. The new Roche automated assays for tacrolimus and cyclosporine will enhance therapeutic drug monitoring (TDM) of transplant recipients by providing the consistency and accuracy of an automated assay, while enhancing workflows, auditing and reporting capabilities in the laboratory. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - July 2, 2013 Category: Pharmaceuticals Source Type: news
Infant Breast Milk Exposure to Tacrolimus Negligible Infant Breast Milk Exposure to Tacrolimus Negligible
A new study has found that infant exposure to tacrolimus during breast-feeding is minimal and blood levels of the drug are comparable to those found in bottle-fed infants. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2013 Category: Consumer Health News Tags: Pediatrics News Source Type: news
Tacrolimus breast milk transfer concerns allayed
Breastfeeding mothers taking tacrolimus do not pass the immunosuppressant on to their babies when breastfeeding, study results show. (Source: MedWire News - Ob/Gyn)
Source: MedWire News - Ob/Gyn - January 30, 2013 Category: OBGYN Source Type: news
Tacrolimus breast milk transfer concerns allayed
Breastfeeding mothers taking tacrolimus do not pass the immunosuppressant on to their babies when breastfeeding, study results show. (Source: MedWire News - Pediatrics)
Source: MedWire News - Pediatrics - January 29, 2013 Category: Pediatrics Source Type: news
Mothers Taking Immunosuppressant Drug Ok To Breast Feed
Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The findings are good news for young women who have received an organ transplant in the past or who are taking the drug for other reasons... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 28, 2013 Category: Consumer Health News Tags: Women's Health / Gynecology Source Type: news
Breastfeeding OK for mothers taking immunosuppressant drug, study suggests
Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a new study. The findings are good news for young women who have received an organ transplant in the past or who are taking the drug for other reasons. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 24, 2013 Category: Science Source Type: news
After liver transplant for HCV, better antiviral results with cyclosporine
NEW YORK (Reuters Health) - In patients transplanted for hepatitis C cirrhosis, the virus inevitably
recurs. Now a new meta-analysis suggests that cyclosporine-based immunosuppression may be associated with a better
response to antiviral therapy after transplant than tacrolimus-based protocols. (Source: Modern Medicine)
Source: Modern Medicine - January 2, 2013 Category: Journals (General) Source Type: news
UPDATE: After liver transplant for HCV, better antiviral results with cyclosporine
NEW YORK (Reuters Health) - In patients transplanted for hepatitis C cirrhosis, the virus inevitably
recurs. Now a new meta-analysis suggests that cyclosporine-based immunosuppression may be associated with a better
response to antiviral therapy after transplant than tacrolimus-based protocols. (Source: Modern Medicine)
Source: Modern Medicine - January 2, 2013 Category: Journals (General) Source Type: news
